A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

Exclusion Criteria11

• History or presence of significant medical/surgical condition including any acute illness or major surgery considered to be clinically significant or that could impact efficacy assessments.
• Any coexisting conditions which may interfere with outcome assessments (eg, severe diabetic neuropathy).
• Concurrent or previous use of rituximab, cyclophosphamide, mycophenolate mofetil, azathioprine, or cyclosporine. If a participant has previously used these medications, the last dose must be at least 6 months prior to randomization.
• Currently or previously on complement inhibitors including in a clinical trial setting.
• Prior history (at any time) of N. meningitidis infection.
• Diagnosis of an autoimmune disorder other than MMN.
• Positive test results for active human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibodies during Screening.
• History of active malignancy within 5 years prior to Screening, except basal cell carcinoma of the skin, curatively resected squamous cell carcinoma of the skin, cervical carcinoma in situ curatively treated or low-grade prostate adenocarcinoma for which appropriate management is observation alone.
• Participation in another clinical study of an investigational drug within 90 days or 5 half-lives of the investigational agent (whichever is longer) prior to randomization (Day 1).
• Any other overlapping condition for which the condition or treatment of the condition may affect the study assessments or outcomes.
• Any other condition, including mental illness or prior therapy, that in the opinion of the Investigator would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.